Skip to content

LeMaitre Vascular LMAT Unrealized Gain (Loss) on Investments

Unrealized Gain (Loss) on Investments at other companies

Axogen logo
AxogenAXGN

Other financials

Income statement

See full
Revenue$66.6M+11.2%
Gross profit$48.4M+16.8%
Operating income$17.8M+40.8%
Net income$15.7M+42.4%
EPS (diluted)$0.68+41.7%

Balance sheet

See full
Cash & equivalents$26.9M+6.0%
Total debt$20.9M+20.6%
Total equity$406.6M+17.0%
Total assets$629.5M+13.2%

Cash flow

See full
Operating cash flow$15.1M+67.0%
CapEx$2.8M+101%
Free cash flow$12.3M+60.8%

Valuation

See full
Market cap$2.11B+31.4%

Profitability

See full
Gross margin72.4%+3.6pp
Operating margin28.5%+5.1pp
Net margin24.3%+4.4pp
FCF margin30.9%+12.7pp

Returns & leverage

See full
Return on equity16.5%+2.8pp
Debt / equity0.1×0.0×
Current ratio14.3×-2.2×

Where this comes from

Reported directly by LeMaitre Vascular in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The official record: LeMaitre Vascular’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about LeMaitre Vascular's unrealized gain (loss) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LeMaitre Vascular's unrealized gain (loss) on investments?
LeMaitre Vascular (LMAT) reported unrealized gain (loss) on investments of -$133.75K in Q4 2025.